A 2022 meta-analysis published in Cardiovascular Diabetology examining GLP-1 receptor agonist effects on lipid profiles found that semaglutide and tirzepatide produced statistically significant reductions in triglycerides across all trials examined, with the magnitude of reduction correlating with both the degree of weight loss achieved and baseline triglyceride levels, supporting the clinical rationale for GLP-1 use in patients with hypertriglyceridemia alongside obesity
The Phase 3 TRIUMPH-4 trial enrolled 445 adults with obesity and knee osteoarthritis for 68 weeks
Biopsy before treatment for any lesion of concern For any persistent non-healing, ulcerated, growing, asymmetrical or atypical pigmented lip lesion, we biopsy first and treat once histopathology has confirmed the diagnosis
The most common reasons for switching include: Supply and Availability: Global demand for weight loss medications has led to frequent shortages
Lingvay I, Leiter LA (2018) Use of GLP-1 RAs in cardiovascular disease prevention: a practical guide
doi: 10.14310/horm.2002.1681